Patients are at the heart of everything we do at Loxo Oncology, and we continue to be motivated by one goal: to dramatically improve the lives of people living with cancer by developing medicines against genomically defined targets driving cancer growth. Though drug development can be risky and complicated, we work hard to navigate through these complexities for the benefit of patients, their families and caregivers.
Our science is driven by an awareness that every person’s cancer has its own distinct genomic makeup. We believe that every patient should receive genomic testing and when a genomic test identifies a tumor caused by an error in the DNA, there should be a highly targeted medicine to address the underlying vulnerability leading to the cancer.
We focus on developing selective medicines for cancers that are driven by a defining genomic alteration, a so-called oncogenic driver. By turning off the mechanism that is driving the cancer, we aim to reduce tumor size and growth. The success of this approach relies heavily on our ability to create medicines that attack very specific gene variations and identify the patients who are most likely to benefit from these targeted therapies.
We invite you to visit our resources page, complete with useful information and external resources for cancer patients and their caregivers. Our Pipeline section contains information on our programs and their development progress. For additional information about any of the larotrectinib, LOXO-292, and LOXO-195 clinical trials, please refer to www.loxooncologytrials.com.